Sinovac vaccine gets conditional approval
2021-02-08 00:00
Chinas top drug regulator granted conditional market approval to a COVID vaccine developed by domestic drugmaker Sinovac Biotech, the second candidate to receive the green light in the country.  In a statement released on Saturday, Sinovac said that it filed for conditional authorization to the National Medical Products Administration on Wednesday and obtained the approval on Friday.  Sinovac said the conditional approval is based on interim results from two months of phasethree clinical trials overseas, adding that the final analysis data is not ready yet and further confirmation of its safety and efficacy is needed.  The administration said on Saturday that it has instructed Sinovac to move ahead with its trials and submit new research results in a timely manner.  Like the experimental vaccine developed by the Stateowned Sinopharmthe first product to be approved for public use on Dec the Sinovac vaccine uses inactivated viral particles to trigger an immune response and requires two doses administered  to  days apart.  After the initial stages of human trials in China demonstrated adequate safety and effectiveness across all age groups, the company launched phasethree trials in Brazil, Chile, Indonesia and Turkey on July , enrolling about , participants.  The drugmaker said that in clinical trials involving nearly , health workers in Brazil, the vaccine was  percent effective in preventing COVID related deaths, severe cases and cases requiring hospitalization, . percent effective for cases showing symptoms and demanding medical treatment, and . percent effective for mild cases.  In Turkey, the vaccine had a . percent efficacy rate based on interim results from  cases.  We will actively advance phasethree clinical trials and clinical research, as well as push ahead with the products registration and application in other countries and regions, stated the company in its statement.  Sinovacs inactivated vaccine was first approved for emergency use with key groups in China in June, and has gradually gained emergency use approval in an increasing number of countries, including Colombia, Uruguay, Laos as well as in the four countries where latestage trials are underway or completed.  During a briefing on Friday, Mariangela Simao, assistant directorgeneral for Access to Medicine and Health Products at the World Health Organization, said that the Sinovac vaccine is one of four vaccines in very advanced stage of the organizations own emergency use evaluation system, known as the Emergency Use Listing.  With its vaccines in high demand, Sinovac said on Saturday that its second production line has been completed and is expected to open this month, which will double the companys capacity, making it able to produce more than  billion doses of vaccines annually.  We are now scaling up the capacity of filling and packaging to catch up with the pace of producing vaccine fluid, it said.  wangxiaoyuchinadaily.com.cn                                                                                                                                                                                                                                                                   !CDATA            function shareweixin              var ua  navigator.userAgent.toLowerCase              ifiphoneipadipod.testua  ua.matchMicroMessengeri  micromessenger                window.opena.app.qq.comosimple.jsp?pkgnamecom.theotino.chinadailyiosschemeencodeIos                            else ifandroid.testua  ua.matchMicroMessengeri  micromessenger                window.opena.app.qq.comosimple.jsp?pkgnamecom.theotino.chinadailyandroidschemeencodeAndroid                            else                window.openwww.chinadaily.com.cnmobiledaily.html